AI Advances Nasal Antivirals to Combat Flu and COVID-19

Scientists have leveraged artificial intelligence to create innovative nasal antivirals capable of preventing infections from viruses like influenza and COVID-19 before they enter human cells. This research represents a significant shift from traditional treatment methods, which typically focus on managing infections after they occur, to a proactive approach aimed at blocking viruses at their entry point.

The breakthrough is particularly notable at Washington State University, where researchers utilized AI and molecular simulations to identify a crucial interaction that facilitates viral entry. The findings, published in the journal Nanoscale and reported by ScienceDaily, focus on a fusion protein utilized by herpes viruses. By examining thousands of amino acid interactions, the AI model pinpointed one specific interaction vital for the virus’s ability to fuse with host cells. Modifying that interaction in laboratory tests rendered the virus unable to penetrate the cells.

According to lead researcher Jin Liu, the application of AI significantly expedited the discovery process. Instead of relying on extensive trial and error, the simulations streamlined the search for the most critical interaction. While the research initially concentrated on herpes viruses, the implications extend to various pathogens, including those responsible for respiratory infections.

AI-Engineered Nasal Antiviral Platform

In a parallel development, researchers at KAIST have engineered an AI-driven nasal antiviral platform specifically designed to combat rapidly mutating respiratory viruses. Detailed in coverage by MedicalXpress, the team focused on redesigning interferon-lambda, a natural immune protein known for its role in inhibiting viral replication. Previous formulations of this protein struggled with stability due to degradation from heat, enzymes, and mucus.

Using AI protein design, the researchers reinforced weak structural areas and modified the protein’s surface to enhance its stability and prevent clumping. The redesigned interferon-lambda was then combined with advanced delivery technology, including encapsulation in nanoliposomes, which allowed the antiviral to adhere to the nasal lining for extended periods.

Animal studies involving influenza demonstrated that the AI-enhanced nasal spray reduced viral levels in the nasal cavity by over 85 percent. Importantly, this formulation remained stable at high temperatures and effectively diffused through thick mucus, making it an attractive option for practical use in real-world scenarios. A nasal spray that does not require strict cold storage could be rapidly deployed during outbreaks and utilized in regions with limited healthcare infrastructure.

Researchers envision adapting this approach for use against COVID-19 and other fast-evolving respiratory threats. The studies underscore a significant trend in antiviral research: rather than continuously adapting to ever-changing viral strains, scientists are concentrating on universal mechanisms such as cell entry and early immune responses. By preventing viruses from establishing infections, nasal antivirals could complement existing vaccines. While vaccines prepare the immune system over time, nasal sprays offer immediate and localized protection during periods of heightened exposure.

Despite the promising results, researchers stress that further testing is necessary before human applications can begin. Clinical trials will be required to verify safety, appropriate dosage, and effectiveness across various viruses. Nevertheless, the integration of AI into the discovery and design process marks a significant advancement in the field. As these technologies continue to evolve, they may enable researchers to respond more swiftly to emerging viral threats and lessen reliance on reactive treatments.

The findings suggest a future where preventing viral infections could potentially be as straightforward as a nasal spray, offering hope for enhanced public health responses to respiratory viruses.